GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » YoY EPS Growth

Pharmala Biotech Holdings (XCNQ:MDMA) YoY EPS Growth : 0.00% (As of Feb. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Pharmala Biotech Holdings's YoY EPS Growth for the quarter that ended in Feb. 2025 was 0.00%.

Pharmala Biotech Holdings's Earnings per Share (Diluted) for the three months ended in Feb. 2025 was C$-0.01.

Pharmala Biotech Holdings YoY EPS Growth Historical Data

The historical data trend for Pharmala Biotech Holdings's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings YoY EPS Growth Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
YoY EPS Growth
- 66.67 - -

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24 Feb25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 100.00 100.00 - -

Pharmala Biotech Holdings YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Pharmala Biotech Holdings's YoY EPS Growth for the fiscal year that ended in Aug. 2024 is calculated as:

YoY EPS Growth (A: Aug. 2024 )
=(Earnings per Share (Diluted) (A: Aug. 2024 )-Earnings per Share (Diluted) (A: Aug. 2023 ))/ | Earnings per Share (Diluted) (A: Aug. 2023 ) |
=(-0.01--0.01)/ | -0.01 |
=0.00 %

Pharmala Biotech Holdings's YoY EPS Growth for the quarter that ended in Feb. 2025 is calculated as:

YoY EPS Growth (Q: Feb. 2025 )
=(Earnings per Share (Diluted) (Q: Feb. 2025 )-Earnings per Share (Diluted) (Q: Nov. 2023 )) / | Earnings per Share (Diluted) (Q: Nov. 2023 )) |
=(-0.01-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » YoY EPS Growth
Comparable Companies
TSXV:SBM TSXV:KNE XCNQ:TELI TSX:CSCI XCNQ:PREV TSXV:HEM XCNQ:BETR XCNQ:PHRM XCNQ:BIOV TSX:RVX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MDXXF:USA
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.
Executives
Fraser Macdonald Director
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines